Abstract
Current vaccine research is now heavily focused on improving the efficacy and potency of sub-unit peptide vaccines. Many successful vaccines developed in past decades have been able to sufficiently prime proper immune responses without the use of any specific adjuvant immune mediators. Due to the intrinsic nature of more immune-evading pathogens and neoplasms, novel “tricks” are needed to elucidate a proper and protective immune response. It is important to note that without cytokines, proper execution of the immune response would be completely inhibited. They are responsible for the recruitment and chemo-tactic movement of most innate cellular effectors such as polymorphonucleocytes (PMN), macrophages, and dendritic cells. Most importantly, the entire Th1/Th2 balance is completely dependent on the unique nature and signature of differential cytokine production. These expression signatures are crucially needed to tip the scale either way, depending on which immune reaction is appropriate. This review will specifically explain the use of Th1 inducing cytokines as an adjuvant in current vaccine development. This rapidly developing field aims to produce more powerful and effective Th1 responses in the hopes of improving the treatment of cancer, intracellular infectious agents, and autoimmune diseases.
Keywords: Vaccines, sub-unit vaccines, peptides, cytokines, adjuvants, Th1/Th2 responses
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants
Volume: 8 Issue: 4
Author(s): Sebastian Di Cesare, Daniel Abourbih, Rubens N. Belfort, Luca A. Petruccelli and Miguel N. Burnier Jr.
Affiliation:
Keywords: Vaccines, sub-unit vaccines, peptides, cytokines, adjuvants, Th1/Th2 responses
Abstract: Current vaccine research is now heavily focused on improving the efficacy and potency of sub-unit peptide vaccines. Many successful vaccines developed in past decades have been able to sufficiently prime proper immune responses without the use of any specific adjuvant immune mediators. Due to the intrinsic nature of more immune-evading pathogens and neoplasms, novel “tricks” are needed to elucidate a proper and protective immune response. It is important to note that without cytokines, proper execution of the immune response would be completely inhibited. They are responsible for the recruitment and chemo-tactic movement of most innate cellular effectors such as polymorphonucleocytes (PMN), macrophages, and dendritic cells. Most importantly, the entire Th1/Th2 balance is completely dependent on the unique nature and signature of differential cytokine production. These expression signatures are crucially needed to tip the scale either way, depending on which immune reaction is appropriate. This review will specifically explain the use of Th1 inducing cytokines as an adjuvant in current vaccine development. This rapidly developing field aims to produce more powerful and effective Th1 responses in the hopes of improving the treatment of cancer, intracellular infectious agents, and autoimmune diseases.
Export Options
About this article
Cite this article as:
Di Cesare Sebastian, Abourbih Daniel, Belfort N. Rubens, Petruccelli A. Luca and Burnier Jr. N. Miguel, Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2009; 8 (4) . https://dx.doi.org/10.2174/187152309789839046
DOI https://dx.doi.org/10.2174/187152309789839046 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endothelial Chemokines in Autoimmune Disease
Current Pharmaceutical Design Recent Patents on Immunoregulatory DNA Vaccines for Autoimmune Diseases and Allograft Rejection
Recent Patents on DNA & Gene Sequences Vitiligo in Children: A Birds Eye View
Current Pediatric Reviews Involvement of IL-1R/TLR Signalling in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Molecular Medicine Nano-formulations for Diagnostics and Therapeutics of Foot-and-Mouth Disease in Animals
Nanoscience & Nanotechnology-Asia The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations
Current Drug Targets The TGF-β 1/Foxp3 Regulatory Axis in Immune Self-Tolerance: Implications for Health and Disease
Inflammation & Allergy - Drug Targets (Discontinued) Role of the Immune System in Autism Spectrum Disorders (ASD)
CNS & Neurological Disorders - Drug Targets Protein Kinase Inhibitors for the Treatment of Inflammation - An Overview
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Tissular Senescence and Modifications of Oral Ecosystem in the Elderly: Risk Factors for Mucosal Pathologies
Current Aging Science Protein Kinases as Drug Targets in Human and Animal Diseases
Current Enzyme Inhibition Multivalent Compounds for Antigen-Specific B Cell Tolerance and Treatment of Autoimmune Diseases
Current Medicinal Chemistry The Soluble CTLA-4 Receptor and its Emerging Role in Autoimmune Diseases
Current Immunology Reviews (Discontinued) Crystallization and Preliminary X-Ray Studies of the Fab Fragment from a Humanized Version of the Mouse Anti-Human Fas Antibody Hfe7a
Protein & Peptide Letters Mesenchymal Stem Cells Induced In Vitro Generated Regulatory-T Cells: Potential Soldiers of Transplantation Biology
Current Biotechnology Pulmonary Infections in the Era of Biological Agents
Current Respiratory Medicine Reviews CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Neuropeptide Receptors in Intestinal Disease: Physiology and Therapeutic Potential
Current Pharmaceutical Design Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Immune Cell Entry to Central Nervous System - Current Understanding and Prospective Therapeutic Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets